Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) EBT Margin (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed EBT Margin for 14 consecutive years, with 69.79% as the latest value for Q4 2025.

  • Quarterly EBT Margin fell 7215.0% to 69.79% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 38.7% through Dec 2025, down 3476.0% year-over-year, with the annual reading at 20.71% for FY2025, 478.0% down from the prior year.
  • EBT Margin for Q4 2025 was 69.79% at Aytu Biopharma, down from 14.15% in the prior quarter.
  • The five-year high for EBT Margin was 20.69% in Q1 2025, with the low at 220.22% in Q1 2022.
  • Average EBT Margin over 5 years is 43.18%, with a median of 25.47% recorded in 2022.
  • The sharpest move saw EBT Margin plummeted -14801bps in 2021, then soared 18855bps in 2023.
  • Over 5 years, EBT Margin stood at 49.95% in 2021, then surged by 49bps to 25.47% in 2022, then surged by 129bps to 7.46% in 2023, then crashed by -68bps to 2.35% in 2024, then plummeted by -3064bps to 69.79% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 69.79%, 14.15%, and 128.46% for Q4 2025, Q3 2025, and Q2 2025 respectively.